Ikarian Capital, LLC Incyte Corp Call Options Transaction History

Ikarian Capital, LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2021 Feb 14, 2022	SELL	$63.34 - $74.11 $6.25 Million - $7.31 Million	-98,700 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$68.67 - $84.02 $6.96 Million - $8.51 Million	-101,300 Reduced 50.65%	98,700 $6.79 Million
Q1 2021 May 17, 2021	BUY	$76.02 - $100.5 $15.2 Million - $20.1 Million	200,000 New	200,000 $16.3 Million
Q4 2020 Feb 12, 2021	SELL	$80.74 - $97.7 $12.1 Million - $14.7 Million	-150,000 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$74.18 - $108.93 $11.1 Million - $16.3 Million	150,000 New	150,000 $15.6 Million
Q1 2020 May 15, 2020	SELL	$63.18 - $85.97 $5.05 Million - $6.88 Million	-80,000 Closed	0 $0
Q4 2019 Jan 31, 2020	BUY	$73.04 - $95.72 $5.84 Million - $7.66 Million	80,000 New	80,000 $6.99 Million

641

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.9B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.